Female sexual disorders have historically been treated with multiple non-medical and off-label medical therapies by a limited number of experienced clinicians. Yet, most therapies have insufficient clinical evidence to support their safety and efficacy. Thus, the development of safe and effective therapies for the treatment of sexual disorders in women is critical to improving the overall management of these conditions, and increasing access to care. The International Society for the Study of Women’s Sexual Health (ISSWSH) supports the role of biotechnology and pharmaceutical companies, and other investigators developing novel therapies for female sexual dysfunction. ISSWSH rejects a “one size fits all” approach to treating female sexual dysfunction due to the multiplicity of biopsychosocial factors that impact sexual health. The concept of personalized medicine, and the availability of multiple therapeutic options are critical in this field.
ISSWSH membership comes with several benefits, one of which is access to Clinical Pearls. Written and reviewed by the Practice Pearls Committee, clinical pearls provide small bits of free standing, clinically relevant information based on experience or observation.1 These Clinical Pearls can provide guidance to practitioners dealing with clinical issues for which controlled data do not exit.
1Lorin MI, Palazai DL, Ward MA. What is a clinical pearl and what is its role in medical education? Med Teach. 2008;30(9-10):870-874.
You will find the Clinical Pearls under "Your ISSWSH Resources".
The following information is posted by ISSWSH members and is not necessarily endorsed by the ISSWSH.